Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-09
M
Martin J. Cannon
Federal Grant PI
High Impact
Professor
Also affiliated: Scripps Research Institute (1988); University of London (1983); Royal Veterinary College (1983–1988); University of Michigan (1998); University of Arkansas Medical Center (1999–2025); University of Arkansas System (2000–2002); Scripps Clinic (1988–1990); National Institute for Medical Research (1989); University of Brescia (1999–2004)
44 h-index
149 pubs
5,988 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Martin J. Cannon's research focuses on developing and evaluating novel immunotherapies for cancer. He has investigated the potential of engineered dendritic cell vaccines to stimulate CD4 T cell-dependent antitumor immunity in ovarian cancer, aiming to overcome resistance to immune checkpoint blockade. His work also explores the repurposing of existing vaccines, such as the live attenuated trivalent MMR vaccine, as a cost-effective cancer immunotherapy.
Cannon's laboratory has characterized different viruses as potential oncolytic virotherapy platforms. This includes research on Myxoma virus, examining its ability to stimulate type 1 interferon responses and induce unique transcriptomic changes in human monocytes and macrophages. Additionally, he has studied Morreton virus for its potential in treating liver cancers and Jurona virus in combination with immune checkpoint blockade for hepatocellular carcinoma. His group also investigates strategies to enhance the effectiveness of virotherapy in pancreatic cancer by targeting the tumor stroma to improve resectability.
With a career marked by significant scholarly output, Cannon has published 158 papers, accumulating over 5,900 citations and an h-index of 44. He has secured federal funding from the NIH/National Cancer Institute for his work on Th17-DC immunotherapy for ovarian cancer and from the NIH/NIH Office of the Director as a Co-PI on research concerning platelets in radiation-induced immune dysregulation. He is recognized as a high-impact researcher and maintains active collaborations with researchers at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 44
- Publications: 149
- Citations: 5,988
Positions
-
Professor publications 1997–2026University of Arkansas for Medical Sciences Microbiology and Immunology Institutional directory
Selected Publications
-
Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)
-
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)
-
A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer (2025)
-
A Replication‐Defective Myxoma Virus Inducing Pro‐Inflammatory Responses as Monotherapy and an Adjuvant to Chemo‐ and DC Immuno‐Therapy for Ovarian Cancer (2025)
-
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)
-
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)
-
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)
-
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)
-
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade (2023)
-
Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023)
-
Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023)
-
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)
-
Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages (2022)
Federal Grants 2 $815,076 total
NIH
Contact PI
Mar 2024 - Feb 2027
NIH
Co-PI
Jul 2022 - May 2027
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Enhancement of Th17-Inducing DC Vaccination for Ovarian Cancer Through PARPi-Mediated Activation of Innate Immunity in the Tumor Microenvironment Congressionally Directed Medical Research Programs
- Improvement of cellular immunotherapy during dysbiosis NIH/Nat. Cancer Institute
- Dendritic cell activation of therapeutic Th17 responses against ovarian cancer The Mary Kay Foundation
- Identification of Druggable Targets to Complement Melanoma Therapy NIH
- Th17-inducing vaccine strategies for preventing progression of ovarian cancer NIH/Nat. Cancer Institute via Mayo Clinic
- Dendritic cell vaccination and immune regulation in ovarian cancer US Department of the Army
- Mechanisms of Combinatorial Therapy to Enhance Anti-PD-1 Immune Checkpoint Inhibition for Ovarian Cancer US Department of Defense
- CD 8+ Cytotoxic T Cell Responses to Novel Ovarian Cancer Antigens (immunotherapy, ovarian cancer, gynecologic oncology, cytotoxic T lymphocytes, dendr US Department of the Army
- Understanding and targeting myeloid populations in ovarian cancer for enhancing therapeutic effects Ovarian Cancer Research Fund Alliance
- Dendritic cell immunotherapy for ovarian cancer NIH
- CD206-targeted alleviation of immune suppression by ovarian tumor-associated macrophages US Department of Defense
- Epigenetic regulation of metabolic stress pathways in melanoma infiltrating lymphocytes- Resubmission NIH
- Proteogenomic analysis of responders versus nonresponders in a Phase I clinical trial of Th17-inducing dendritic cell vaccination for advanced stage ovarian cancer US Department of Defense
- Novel target antigens for ovarian cancer immunotherapy NIH
- MAPK pathway modulation in thyroid tumorigenesis NIH
- NanoPhotothermolysis of Breast Tumors: Feasibility with Photothermal Imaging Cubist Pharmaceuticals, Inc.
- Mayo Clinic Ovarian Cancer SPORE - Pilot Project NIH/Nat. Cancer Institute via Mayo Clinic
- Improvement of cellular immunotherapy during dysbiosis- Resubmission NIH
- T-CELL IMMUNOTHERAPY OF EBV ASSOCIATED LYMPHOMA NIH
- Preventing immune system dysregulation during deep-space missions by Tocofexol, a modified isomer of vitamin E - AA request National Aeronautics & Space Administration via Arkansas Space Grant Consortium
Collaboration Network
Top Collaborators
Alessandro D. Santin
University of Arkansas at Little Rock (US)
39 shared publications
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Induction of Human Papillomavirus-Specific CD4+and CD8+Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
Showing 5 of 39 shared publications
Stefania Bellone
University of Arkansas at Little Rock (US)
32 shared publications
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
Showing 5 of 32 shared publications
Sërgio Pecorelli
University of Arkansas at Little Rock (US)
32 shared publications
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Induction of Human Papillomavirus-Specific CD4+and CD8+Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
Showing 5 of 32 shared publications
Michela Palmieri
University of Arkansas for Medical Sciences
18 shared publications
In database
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
Showing 5 of 18 shared publications
Antonella Ravaggi
University of Arkansas at Little Rock (US)
15 shared publications
- Induction of Human Papillomavirus-Specific CD4+and CD8+Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
- Secretion of vascular endothelial growth factor in ovarian cancer.
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
Showing 5 of 15 shared publications
Groesbeck P. Parham
University of Arkansas at Little Rock (US)
15 shared publications
- Induction of Human Papillomavirus-Specific CD4+and CD8+Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Secretion of vascular endothelial growth factor in ovarian cancer.
- Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix
- Vaccination with HPV-18 E7–Pulsed Dendritic Cells in a Patient with Metastatic Cervical Cancer
Showing 5 of 15 shared publications
Juan J. Roman
14 shared publications
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
Showing 5 of 14 shared publications
Maurizio Chiriva‐Internati
Texas Tech University (US)
13 shared publications
- Induction of Human Papillomavirus-Specific CD4+and CD8+Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer
- Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer
- Identification of AKAP‐4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer
- Cancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian Cancer
- Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer
Showing 5 of 13 shared publications
Stefania Canè
University of Arkansas for Medical Sciences (US)
12 shared publications
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens Enterotoxin
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
- Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
Showing 5 of 12 shared publications
Everardo Cobos
Texas Tech University (US)
10 shared publications
- Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian Cancer
- Identification of AKAP‐4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer
- Cancer Testis Antigen Vaccination Affords Long-Term Protection in a Murine Model of Ovarian Cancer
- Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer
- Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen
Showing 5 of 10 shared publications
Paul L. Hermonat
University of Arkansas at Little Rock (US)
9 shared publications
- Induction of Human Papillomavirus-Specific CD4+and CD8+Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer
- Interleukin-10 Increases Th1 Cytokine Production and Cytotoxic Potential in Human Papillomavirus-Specific CD8+Cytotoxic T Lymphocytes
- Secretion of vascular endothelial growth factor in ovarian cancer.
- Effects of concurrent cisplatinum administration during radiotherapy vs. radiotherapy alone on the immune function of patients with cancer of the uterine cervix
- Phenotypic and Functional Analysis of Tumor-Infiltrating Lymphocytes Compared with Tumor-Associated Lymphocytes from Ascitic Fluid and Peripheral Blood Lymphocytes in Patients with Advanced Ovarian Cancer
Showing 5 of 9 shared publications
Alexei G. Basnakian
University of Arkansas for Medical Sciences
9 shared publications
In database
- Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
Showing 5 of 9 shared publications
Mulu Z. Tesfay
Winthrop Rockefeller Foundation
9 shared publications
In database
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
Showing 5 of 9 shared publications
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
9 shared publications
In database
- Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
Showing 5 of 9 shared publications
Eliana Bignotti
University of Brescia (IT)
8 shared publications
- Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy
- The novel serine protease tumor-associated differentially expressed gene-14 (KLK8/Neuropsin/Ovasin) is highly overexpressed in cervical cancer
- Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix
- In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells
- Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
Showing 5 of 8 shared publications
Similar Researchers
Based on overlapping research topics
Logan Rodgers
University of Arkansas at Fayetteville
Disease Models, Animal
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Mika A. Taylor
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Cancer Treatment and Pharmacology
Microbial infections and disease research
Abul B. Kazi
University of Arkansas at Pine Bluff
Disease Models, Animal
Cancer Treatment and Pharmacology
Microbial infections and disease research
Hailey Kristian
University of Arkansas for Medical Sciences
Disease Models, Animal
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
Oncolytic Virotherapy
Disease Models, Animal
Cancer Treatment and Pharmacology
Duah Alkam
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Cancer Treatment and Pharmacology
Microbial infections and disease research